Cenisertib
Product Specifications
Product Name Alternative
AS-703569; R-763
UNSPSC Description
Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3].
Target Antigen
Akt; Aurora Kinase; Bcr-Abl; FLT3; STAT
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Epigenetics;JAK/STAT Signaling;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cenisertib.html
Purity
99.86
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]
Molecular Weight
451.54
References & Citations
[1]Peter B, et al. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia. 2018 Apr;32(4):1016-1022.|[2]McLaughlin J, et al. Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113.|[3]Maryam Shariati, et al. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019 Nov;28(11):977-988.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-13072/Cenisertib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-13072/Cenisertib-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
871357-89-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
NBP2-50389JF549 0.1 mL
Mouse Monoclonal ERO1LB Antibody (M37-P5D11) [Janelia Fluor 549]
Ask
View Details 